Sitravatinib

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

可选规格

包装

价格

促销价

数量
5mg

￥898.00

499.00

- +
10mg

￥1293.00

899.00

- +
50mg

￥3600.00

1500.00

- +
100mg

￥5713.00

2800.00

- +
200mg

￥9171.00

5200.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/L.

货号：ajci22906
CAS：1123837-84-2
分子式：C33H29F2N5O4S
分子量：629.68
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Sitravatinib is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth with IC50 of 3980 nmol/Lin vitro: MGCD516 is superior to other multi-kinase inhibitors in inhibiting cell proliferation, RTK phosphorylation, and phosphorylation of downstream effectors. MGCD516 is unique in a way that it has broad spectrum activity against many RTKs including c-Met, c-Kit, Axl, PDGFR, and Eph receptors that are known to play a role in driving sarcoma cell growthIn vivo: MGCD516 induces significant tumor growth suppression than imatinib and crizotinib.

参考文献:
[1]. Patwardhan PP et al. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget, 2016 Jan 26;7(4):4093-109.